Endpoints News, July 7, 2023: FDA wants to revamp its Advisory Committee meetings but will they make them better or worse? The votes aren’t the problem. We explain that the conflicts of interest of committee members is “outrageous.”
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic
STAT News, July 5, 2023: Novo Nordisk gave doctors 450,000 free restaurant meals and snacks in 2022 while promoting drugs like Ozempic for weight loss. One doctor got 183 meals. Some got free trips to Paris or Hawaii. Can those doctors be objective about the risks and benefits of the drugs?
Read More »Alzheimer’s Patient Registry Raising Questions as Drug OK Nears
Bloomberg News, June 29, 2023: If Leqembi is approved for very early Alzheimer’s, CMS and NCHR explain how the Medicare registry will help patients make informed decisions about whether the benefits are likely to outweigh the risks for them for this expensive and risky treatment. But PhRMA and aligned patient groups complain.
Read More »Cambridge biotech Sarepta wins fast-track approval for the first muscular dystrophy gene therapy
The Boston Globe, June 22, 2023: FDA has approved Sarepta’s gene therapy for Duchenne muscular dystrophy, which will cost $3.2 million per patient. FDA’s Peter Marks praises the drug as if he is a Sarepta salesman, and NCHR explains why this political compromise is harmful to patients.
Read More »Pricey Alzheimer’s Drug Coverage Hinges on FDA Decision
Bloomberg News, June 15, 2023: If Leqembi is approved, it will take time for doctors to arrange for patients to be tested for mild cognitive impairment and amyloid plaques on the brain, get the Leqembi infusions, and sign up patients for a registry. NCHR praises the CMS Registry as a good choice, but industry-funded groups complain.
Read More »